Document:

EX-10.9

 Exhibit 10.9 

Matthew J. Plunkett, PhD 
 ### 

31 December 2020 
 Re: Employment
Terms 
 Dear Matt: 
 Imago BioSciences,
Inc., a Delaware corporation (the “Company”), is pleased to offer you the position of Chief Financial Officer, effective as of 1 January 2021 (the date you commence employment with the Company, the “Start
Date”), in which you will be responsible for such duties as are normally associated with such positions and such other duties as shall be assigned by Hugh Young Rienhoff, Jr., the CEO. You will report directly to the CEO. Imago is
headquartered in offices located in San Carlos and South San Francisco, California, but you will work remotely, notwithstanding all business travel as necessary or appropriate to fulfill your responsibilities. In the course of your employment with
Company, you will be subject to and required to comply with all company policies, and applicable laws and regulations. 
 You will be paid a
base salary at the annual rate of $375,000.00, less payroll deductions and all required withholdings, pro-rated for any partial employment hereunder. Your salary will be payable monthly in accordance with the
Company’s standard payroll policy. There will be an annual review of your salary and benefits coinciding with the end of fiscal year 2021 

In addition to the above, at the discretion of the Company, you will be eligible to receive an annual cash performance bonus of up to 25% of
your base salary. The amount of any performance bonus will be determined by the Board based on your personal performance and that of the Company. Any performance bonus will be paid to you by
March 30th of the calendar year immediately following the year for which it was earned. 

You will be eligible for all employee benefits and benefit plans, such as medical insurance, sick leave, retirement, vacations and holidays to
the extent applicable generally to other executive officers of the Company. Such benefits shall include in each calendar year holidays set forth by the Company and 20 days or 160 hours of vacation; these hours accrue on a monthly basis of
13.33 hours per month. Details about these benefits will be provided in an Employee Handbook and in Summary Plan Descriptions, which will be prepared by the Company and made available for your review in due course. The Company reserves the
right to terminate, modify or add to its benefits and benefit plans at any time. You will be reimbursed for all reasonable expenses incurred by you in performance of your duties in accordance with the Company’s reimbursement policies. 

Subject to approval by the board of directors of the Company (the “Board”), you shall be granted an option, pursuant to the
Company’s 2012 Equity Incentive Plan (the “Plan”), to purchase 1.1% of the Company’s Fully Diluted Shares (defined below). The Option will have an exercise price equal to the fair market value per share of the
Company’s common stock on the date of grant, which is anticipated to be $0.50 per share. Twenty-five percent (25%) of the shares subject to the Option (rounded down to the next whole number of shares) shall vest on the first anniversary of the
Start Date and 1/48th of the shares subject to the Option shall vest monthly thereafter so that 

			
	Matthew J. Plunkett, Ph.D.	  	31 December 2020

  

 
one hundred percent (100%) of the shares subject to the Option are vested on the fourth anniversary of the Start Date, subject to your continued service to the Company through the applicable
vesting date. The Option shall be an “incentive stock option” to the maximum extent permitted under applicable tax laws, shall have standard “early exercise” right and shall be subject to the terms and conditions of the Plan and
related form of stock option agreement. For purposes hereof, “Fully Diluted Shares” shall be calculated by adding the number of outstanding shares of capital stock of the Company (on an
as-converted to common stock basis) plus the number of shares of Company common stock or other securities (on an as-converted to common stock basis) that are subject to
issuance under outstanding warrants or options without regard to any vesting or similar restrictions and including (without double counting) the number of shares of Company common stock that are reserved for future issuance (but not yet issued)
under any equity incentive or similar plan (including but not limited to the Plan) or reserve that has been approved by the Board (including for clarity shares of preferred stock issuable in subsequent tranches or closing of existing financing
agreements), in each case, as of immediately following (and including) the grant of the Option pursuant to this paragraph. Subject to the discretion of the Board, you may be eligible to receive additional grants of stock options or purchase rights
from time to time in the future, on such terms and subject to such conditions as the Board shall determine as of the date of any such grant. 

If your employment is terminated at any time by the Company without Cause (as defined below) or you resign from the Company for Good Reason
(as defined below), then, in addition to any unpaid base salary earned through the termination date and any expenses owed to you and any accrued but unused paid time-off and subject to your (a) continued
compliance with the Confidential Information and Invention Assignment Agreement and (b) delivery to the Company a general release of all claims against the Company and its affiliates in the form attached hereto as
Exhibit B (the “Release”) that becomes effective and irrevocable on or before the Release Expiration Date (as defined below), you shall be entitled to the following: (i) you shall receive a cash
payment equal to six (6) months of your base salary at the rate in effect immediately prior to your date of termination; such payment shall be made in a cash lump sum, less applicable withholdings, on the first payroll date following the date
your Release becomes effective and irrevocable (or as otherwise provided in the Section 409A paragraph below); (ii) during the period commencing on your date of termination and ending on nine (9) month anniversary thereof or, if earlier,
the date on which you become eligible for comparable replacement coverage under a subsequent employer’s group health plan (in any case, the “COBRA Period”), subject to your valid election to continue healthcare coverage under
Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder, the Company shall, in its sole discretion, either (A) continue to provide to you and your dependents, at the
Company’s sole expense, or (B) reimburse you and your dependents for coverage under its group health plan (if any) at the same levels in effect on your date of termination; provided, however, that if (1) any plan
pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code under Treasury Regulation
Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover you or your dependents under its group health plans, or (3) the Company cannot provide the benefit without violating
applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to you in substantially equal monthly installments
over the COBRA Period (or remaining portion thereof); (iii) the vesting and exercisability of the your equity awards shall be accelerated by six (6) months with respect to unvested shares subject thereto

  
 2 

			
	Matthew J. Plunkett, Ph.D.	  	31 December 2020

  

 
effective as of immediately prior to the date of your termination of employment; and (iv) if and only if such qualifying termination of employment occurs during a Change in Control Period
(as defined below), the vesting and exercisability of the your equity awards shall be accelerated with respect to 100% of the unvested shares subject thereto effective as of immediately prior to the date of your termination of employment. To give
effect to the foregoing, upon your date of qualifying termination, (i) the vested portion of such equity awards shall remain outstanding and/or be exercisable for the period(s) of time set forth in the applicable equity award agreements,
(ii) your outstanding equity awards shall cease vesting, and (iii) the unvested shares subject to your outstanding equity awards shall remain outstanding (but unvested) until the earlier to occur of (A) the original expiration date of
the equity award and (B) three (3) month anniversary of the your date of termination (the “Equity Award Period”). In the event a Change in Control has not been consummated by end of the Equity Award Period, then the unvested portion
of your equity awards shall terminate immediately without further action as of such date. 
 For the purposes of this letter agreement,
“Cause” shall mean (A) your willful refusal to perform in any material respect your duties or responsibilities for the Company or its affiliates or willful disregard in any material respect of any financial or other budgetary
limitations established in good faith by the Company; (B) your repeated unexplained or unjustified absence from the Company (it being understood that you’re working remotely as provided above will not constitute “cause” within
the meaning of this clause (B)); (C) your engagement in misconduct that causes material and demonstrable injury, monetarily or otherwise, to the Company or any affiliates, including, but not limited to, misappropriation or conversion of assets of
the Company or any affiliates (other than non-material assets); or (D) your conviction of or entry of a plea of nolo contendere to a felony and/or (E) your material breach of any provision of
the Confidential Information and Invention Assignment Agreement which causes material and demonstrable harm to the Company. Notwithstanding the foregoing, the occurrence of an event or action with respect to subclauses (A) and (B) above shall
not constitute “Cause” unless you are given 30 days to cure an event or action if curable following receipt of a written notice from the Company describing the alleged Cause. 

For purposes of this letter agreement, “Change in Control” shall have the same meaning as defined in the Company’s 2012 Equity
Incentive Plan, as amended. Notwithstanding the foregoing, a “Change in Control” must also constitute a “change in control event,” as defined in Treasury Regulation
Section 1.409A-3(i)(5), with respect to any compensation or benefit that is subject to Section 409A of the Code. For purposes of this letter agreement, “Change in Control Period” shall mean
any time after the date that is three (3) months prior to a Change in Control. 
 For the purposes of this letter agreement, “Good
Reason” shall mean any of the following: (i) a material diminution in your title, authority, duties, responsibilities or base compensation by or with the Company or (ii) the Company’s material breach of this offer letter
agreement. Notwithstanding the foregoing, the occurrence of an event or action shall not constitute “Good Reason” unless (X) you provide advance written notice of your resignation from the Company within ninety (90) days of the
initial occurrence of the event or action giving rise to Good Reason, (Y) the notice specifies that your resignation is effective not less than thirty (30) days, nor more than sixty (60) days, after the date of the written notice, and
(Z) the Company fails to remedy the basis for Good Reason prior to the date of the resignation specified in the written notice. 

  
 3 

			
	Matthew J. Plunkett, Ph.D.	  	31 December 2020

  

 The intent of the parties is that the payments and benefits under this letter agreement
comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued, and,
accordingly, to the maximum extent permitted, this offer letter shall be interpreted to be in compliance therewith. To the extent that any provision of this letter agreement is ambiguous as to its exemption from or compliance with Section 409A
of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or if not exempt from, comply with, Section 409A of the Code. No amount deemed deferred compensation subject to Section 409A of the
Code shall be payable pursuant to this letter unless your termination of employment constitutes a “separation from service” with the Company within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, and the
Department of Treasury regulations and other guidance promulgated thereunder. For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation
Section 1.409A-2(b)(2)(iii)), your right to receive any installment payments under this letter agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such
installment payment shall at all times be considered a separate and distinct payment. To the extent that any reimbursements payable pursuant to this letter agreement are subject to the provisions of Section 409A of the Code, any such
reimbursements payable to you pursuant to this letter agreement shall be paid to you no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the
amount eligible for reimbursement in any subsequent year, and your right to reimbursement under this letter agreement will not be subject to liquidation or exchange for another benefit. Notwithstanding anything in this letter agreement to the
contrary, if you are deemed by the Company at the time of your “separation from service” to be a “specified employee” for purposes of Section 409A of the Code, to the extent delayed commencement of any portion of the
benefits to which you are entitled under this offer letter is required in order to avoid a prohibited distribution under Section 409A of the Code, such portion of your benefits shall not be provided to you prior to the earlier of (i) the
expiration of the six (6)-month period measured from the date of your “separation from service” with the Company or (ii) the date of your death. Upon the first business day following the expiration of the applicable Section 409A
of the Code period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to you (or your estate or beneficiaries), and any remaining payments due to you under this offer letter shall be paid as otherwise provided
herein. In relation to your severance set forth above, the Company shall deliver the Release to you within ten (10) business days following your date of termination, and the Company’s failure to deliver a Release prior to the expiration of
such ten (10) business day period shall constitute a waiver of any requirement to execute a Release. In any case where your date of termination and the Release Expiration Date fall in two separate taxable years, any payments required to be made
to you that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of Section 409A of the Code shall be made in the later taxable year. To the extent that any payments of nonqualified deferred
compensation (within the meaning of Section 409A of the Code) due under this offer letter as a result of your termination of employment are delayed pursuant to this paragraph, such amounts shall be paid in a lump sum on the first payroll date
following the date that you execute and do not revoke the Release (and the applicable revocation period has expired) or, in the case of any payments subject to foregoing sentence, on the first payroll period to occur in the subsequent taxable year,
if later. For purposes of this letter agreement, “Release Expiration Date” shall mean (i) if you are under 

  
 4 

			
	Matthew J. Plunkett, Ph.D.	  	31 December 2020

  

 
40 at the date of termination, the date that is seven (7) days upon which the Company timely delivers the Release to you, and (ii) if you are over 40 at the date of termination,
the date that is twenty-one (21) days following the date upon which the Company timely delivers the Release to you, or, in the event that your termination of employment is “in connection with an exit
incentive or other employment termination program” (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days following such delivery date. 

The Company requires that, as a full-time employee, you devote your full business time, attention, skill, and efforts to the tasks and duties
of your position as assigned by the Company. If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by the Company that will impact your ability to perform your
duties, please discuss that with me in advance of accepting another position. 
 As a condition of employment, you will be required to
(i) sign and comply with a Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as Exhibit A (the “Confidential Information and Invention Assignment Agreement”),
which, among other things, prohibits unauthorized use or disclosure of Company proprietary information, (ii) sign and return a satisfactory I-9 Immigration form providing sufficient documentation
establishing your employment eligibility in the United States, and (iii) provide satisfactory proof of your identity as required by United States law. 

Notwithstanding any of the above, your employment with the Company is “at will”. This means you may terminate your employment with
the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This at-will employment relationship cannot be changed except in a writing signed by a duly authorized member of the Board. 

If you accept this offer, this letter and the Confidential Information and Invention Assignment Agreement shall constitute the complete
agreement between you and the Company with respect to the terms and conditions of your employment. Any prior or contemporaneous representations (whether oral or written) not contained in this letter or the Confidential Information and Invention
Assignment Agreement or contrary to those contained in this letter or the Confidential Information and Invention Assignment Agreement, that may have been made to you are expressly cancelled and superseded by this offer. This offer letter shall be
interpreted and construed in accordance with the laws of the State of California without regard to any conflicts of laws principles. Except as otherwise specified herein, the terms and conditions of your employment may not be changed, except in
another letter or written agreement, signed by you and a duly authorized member of the Board. 
 (Signature Page Follows) 

  
 5 

			
	Matthew J. Plunkett, Ph.D.	  	31 December 2020

  

 Please sign, date, and return this letter to me if you wish to accept employment at the
Company under the terms described above. This offer will expire if not accepted by you by 1 January 2021. If you accept our offer, we would like you to commence your employment with us as soon as practicable. 

I look forward to your favorable reply and to a productive and enjoyable working relationship. 

 

			
	Sincerely,
	
	IMAGO BIOSCIENCES, INC.
		
	By:	 	 /s/ Hugh Young Rienhoff, Jr.

		
	Name:	 	Hugh Young Rienhoff, Jr.
		
	Title:	 	Chief Executive Officer

  

	
	Accepted by:
	
	 /s/ Matthew J. Plunkett, PhD

	Matthew J. Plunkett, PhD
	
	 December 31, 2020

	Date

  
 6 

 Exhibit A 

Confidential Information and Invention Assignment Agreement 

Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 7 

 Exhibit B 

Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5) 

 EXHIBIT C 

TERMINATION CERTIFICATION 

Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)EX-10.10

 Exhibit 10.10 

IMAGO BIOSCIENCES, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM 

This Imago BioSciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this
“Program”) has been adopted under the Company’s 2021 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stock
(the “IPO”). Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan. 
 Cash Compensation

 Effective upon the IPO, annual retainers will be paid in the following amounts to Non-Employee Directors:

  

					
	 Non-Employee Director:
	  	$	40,000	 
	 Non-Executive Chair:
	  	$	30,000	 
	 Audit Committee Chair:
	  	$	15,000	 
	 Compensation Committee Chair:
	  	$	15,000	 
	 Nominating and Corporate Governance Committee Chair:
	  	$	8,000	 
	 Audit Committee Member (non-Chair):
	  	$	7,500	 
	 Compensation Committee Member (non-Chair):
	  	$	5,000	 
	 Nominating and Corporate Governance Committee Member
(non-Chair):
	  	$	4,000	 

 All annual retainers will be paid in cash quarterly in arrears promptly following the end of the applicable calendar quarter,
but in no event more than 30 days after the end of such quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable
positions described above, for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable. 
 Equity Compensation 

 

			
	Initial Stock Option Grant:	  	 Each Non-Employee Director who is initially elected or appointed to serve on the Board after the
IPO shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase 150,000 shares of Common Stock.
  

The Initial Option will be automatically granted on the date on which such Non-Employee Director commences service on
the Board, and will vest as to 1/36th of the shares subject thereto on each monthly anniversary of the applicable date of grant such that the shares subject to the Initial Option are fully vested
on the third anniversary of the grant, subject to the Non-Employee Director continuing in service on the Board through each vesting date.

			
	Annual Stock Option Grant:	  	 Each Non-Employee Director who has, for at least six months, been serving on the Board as of the
date of each annual shareholder meeting of the Company (each, an “Annual Meeting”) shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase
75,000 shares of Common Stock.
  
 The Annual Option will be automatically granted on
the date of the applicable Annual Meeting, and will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.

 The per share exercise price of each Option granted to a Non-Employee Director shall
equal the Fair Market Value of a share of common stock on the date the Option is granted. 
 The term of each Option granted to a Non-Employee Director shall be ten years from the date the Option is granted. 
 No portion of an Initial Option or Annual
Option which is unvested or unexercisable at the time of a Non-Employee Director’s termination of service on the Board shall become vested and exercisable thereafter. 

Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and
any parent or subsidiary of the Company and remain on the Board will not receive an Initial Option, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or
subsidiary of the Company, Annual Options as described above. 
 Change in Control 

Upon a Change in Control of the Company, all outstanding equity awards granted under the Plan and any other equity incentive plan maintained by the Company
that are held by a Non-Employee Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Non-Employee Director’s Award Agreement. 

  
 2 

 Reimbursements 

The Company shall reimburse each Non-Employee Director for all reasonable, documented,
out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties
to the Company in accordance with the Company’s applicable expense reimbursement policies and procedures as in effect from time to time. 

Miscellaneous 
 The other provisions of the Plan
shall apply to the Options granted automatically pursuant to this Program, except to the extent such other provisions are inconsistent with this Program. All applicable terms of the Plan apply to this Program as if fully set forth herein, and all
grants of Options hereby are subject in all respects to the terms of the Plan. The grant of any Option under this Program shall be made solely by and subject to the terms set forth in a written agreement in a form to be approved by the Board and
duly executed by an executive officer of the Company. 
 Effectiveness 

This Program shall become effective upon the consummation of the IPO. 

* * * * * 

  
 3 

 I hereby certify that the foregoing Program was adopted by the Board of Directors of Imago BioSciences, Inc.
on July 1, 2021. 
 * * * * * 
  

					
	 Executed on July 1, 2021.
	 		 	
			
		 		 	/s/ Benjamin Potter
		 		 	Corporate Secretary

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]